Bromocriptine as a Novel Pharmacological Chaperone for Mucopolysaccharidosis IV A-Reference-Cited by-同舟云学术

Bromocriptine as a Novel Pharmacological Chaperone for Mucopolysaccharidosis IV A

Published:2020-06-24 Issue:7 Volume:11 Page:1377-1385
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Olarte-Avellaneda Sergio¹²,Cepeda Del Castillo Jacobo¹,Rojas-Rodriguez Andrés Felipe³,Sánchez Oscar⁴,Rodríguez-López Alexander¹⁵,Suárez García Diego A.¹⁶^ORCID,Pulido Luz Mary Salazar⁷,Alméciga-Díaz Carlos J.¹^ORCID

Affiliation:

1. Institute for the Study of Inborn Errors of Metabolism, Faculty of Science, Pontificia Universidad Javeriana, Bogotá D.C. 110231, Colombia

2. Pharmacy Department, Faculty of Science, Universidad Nacional de Colombia, Bogotá D.C. 11001, Colombia

3. Computational and Structural Biochemistry, Biochemistry and Nutrition Department, Faculty of Science, Pontificia Universidad Javeriana, Bogotá D.C. 110231, Colombia

4. Neurobiochemistry and Systems Physiology, Biochemistry and Nutrition Department, Faculty of Science, Pontificia Universidad Javeriana, Bogotá D.C. 110231, Colombia

5. Chemistry Department, Faculty of Science, Pontificia Universidad Javeriana, Bogotá D.C. 110231, Colombia

6. Faculty of Medicine, Universidad Nacional de Colombia, Bogotá D.C 11001, Colombia

7. Chemistry Department, Faculty of Science, Universidad Nacional de Colombia, Bogotá D.C. 11001, Colombia

Funder

Pontificia Universidad Javeriana

Ministry of Science, Technology and Innovation, Colombia

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.0c00042

Reference37 articles.

1. Enzyme replacement therapy for treating mucopolysaccharidosis type IVA (Morquio A syndrome): effect and limitations

2. Effect of enzyme replacement therapy on the growth of patients with Morquio A

3. Hematopoietic stem cell transplantation for Morquio A syndrome

4. Tailoring the AAV2 capsid vector for bone-targeting

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of Orthosteric and Allosteric Pharmacological Chaperones for Mucopolysaccharidosis Type IIIB;ChemBioChem;2024-07-16

2. Drug Repurposing and Lysosomal Storage Disorders: A Trick to Treat;Genes;2024-02-25

3. Evidence of epigenetic landscape shifts in mucopolysaccharidosis IIIB and IVA;Scientific Reports;2024-02-17

4. Iron oxide-coupled CRISPR-nCas9-based genome editing assessment in mucopolysaccharidosis IVA mice;Molecular Therapy - Methods & Clinical Development;2023-12

5. Carbohydrate‐Based Therapeutics for Lysosomal Storage Disorders;Carbohydrate‐Based Therapeutics;2023-09-05